ADOCIA : announces its financial calendar for 2013 as well as its participation to upcoming investor conferences.

Regulatory News:

Adocia (Paris:ADOC) (NYSE Euronext Paris: FR0011184241 - ADOC), a biotechnology company specialized in the development of 'best-in-class' medicines from already approved therapeutic proteins, announces today its financial calendar for 2013.

February 19, 2013 :		Publication of revenue for Q4 2012 and for 2012 full year.
March 20, 2013 :		Publication of 2012 financial statements.
March 21, 2013		Presentation meeting to investors.
April 24, 2013 :		Publication of revenue for Q1 2013.
June 18, 2013 :		Annual shareholders' meeting at Château de Montchat, Lyon 3°.
September 5, 2013 :		Publication of mid-year financial statements as of June 30, 2013.
September 6, 2013 :		Presentation meeting to investors.
October 23, 2013 :		Publication of revenue for Q3 2013.

Next scheduled events

Adocia will attend the Biotech Showcase 2013 from January 7 to 9, 2013 in San Francisco (USA) and the ODDO Forum Midcap in Lyon (France) on January 10 and 11, 2013.

Adocia is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.adocia.com). All corporate information on the company such as its financial statements or its corporate presentations is available on the company's website, in the Investor's section, « Regulated Information ».

About Adocia :

"Innovative medicine for everyone, everywhere"

Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.

Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD20 billion (USD17 billion for insulin therapy and USD3 billion for diabetic foot ulcer healing).

Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.

Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Adocia also confirmed the value of its technology for the formulation of a fast-acting insulin analog by signing an exclusive worldwide license agreement with a major pharmaceutical company. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.

To be a global leader for the formulation of therapeutic proteins

Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.

Adocia's therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.

Adocia is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index

Next Biotech.

For more information: www.adocia.com

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" sections of the prospectus registered by the Autorité des marchés financiers on January 25, 2012 under number 12-034 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

Gérard Soula, [phone]
Chairman and CEO of Adocia
[e-mail]
or
Press Relations
Andrew Lloyd & Associates
Juliette dos Santos, [phone]
[e-mail]
or
Financial communication & Investor Relations
NewCap
Pierre Laurent, [phone]
[e-mail]